Blake Insomnia Therapeutics Inc. announced that it has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada. The Phase II clinical trial will investigate the effect of ZLX-1 on insomnia, and is a critical milestone for this novel insomnia treatment on its way to final approval. The trial results are essential for validating the ZLX-1 concept and for designing the Phase IIb trial to follow.